- Atezolizumab, sold
under the
brand name
Tecentriq among others, is a
monoclonal antibody medication used to
treat urothelial carcinoma, non-small cell...
-
deletion and who have been
treated with at
least one
prior therapy. 2016:
Tecentriq (atezolizumab): First-in-class anti-PD-L1
antibody for the
treatment of...
-
vemurafenib and
atezolizumab (
Tecentriq) to
treat melanoma.
Cobimetinib is a MEK inhibitor. Cotellic, Zelboraf, and
Tecentriq are all
marketed by Genentech...
-
small cell lung cancer: 1.
Nivolumab (Opdivo), and 2.
Atezolizumab (
Tecentriq)
Tecentriq treatment costs on
average $13,200 per month,
depending on the dosage...
- (tolcapone), for parkinson's disease,
licensed by
Mylan and
Bausch Health.
Tecentriq (atezolizumab), for non-small cell lung cancer.
TNKase (tenecteplase)...
- (MEDI0680) by
AstraZeneca Acrixolimab (YBL-006) by Y-Biologics
Atezolizumab (
Tecentriq) is a
fully humanised IgG1 (immunoglobulin 1)
antibody developed by Roche...
-
endometrial cancer,
squamous cell carcinoma,
biliary tract cancer Atezolizumab Tecentriq Genentech/Roche PD-L1 2016
bladder cancer, non-small cell lung cancer...
- million. 2016:
Cooperation between Osaka University and
Chugai 2018:
Tecentriq , a
cancer drug, is
launched 2020 – FDA
approved satralizumab (Enspryng)...
-
humanized CD52 2001 B-cell
chronic lymphocytic leukemia (CLL)
Atezolizumab Tecentriq humanized PD-L1 2016
bladder cancer Avelumab Bavencio human PD-L1 2017...
-
public domain. "FDA
updates prescribing information for
Keytruda and
Tecentriq". U.S. Food and Drug
Administration (Press release). 16
August 2018. Archived...
